Depomed trial shows Glumetza plus sulfonylurea treatment effective in glycemic control in type 2 diabetes

By Lisa Kerner

Charlotte, N.C., June 7 - Depomed, Inc. said results of a second phase 3 clinical trial with Glumetza (metformin hydrochloride extended-release tablets) for the treatment of type 2 diabetes mellitus demonstrated that adding Glumetza, once-daily version of metformin, to a sulfonylurea treatment regimen provided more effective glycemic control than the use of the sulfonylurea alone.

The results were published in the June issue of Diabetes: A Journal of the American Diabetes Association 2006; according to a company news release.

"This is very important data that further support Glumetza as a potential first line choice for controlling diabetes," chief scientific officer Bret Berner said in the release.

"We feel that Glumetza is a unique formulation of metformin that increases the potential of what this drug can offer. Glumetza leverages Depomed's AcuForm drug delivery technology, which is designed to enhance tolerability and reduce the gastrointestinal side effects associated with oral medications."

Depomed is a specialty pharmaceutical company located in Menlo Park, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.